This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New Strong Buy Stocks for July 3rd
by Zacks Equity Research
CRON, CDE, SOUHY, PRM and STNG have been added to the Zacks Rank #1 (Strong Buy) List on July 3, 2025.
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -180% and 21.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 5.71% and 1.35%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -27.59% and 37.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Cronos Group (CRON) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of 0% and 13.43%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include Amneal Pharmaceuticals, Cronos Group, Carriage Services, Business First Bancshares and Amphenol
by Zacks Equity Research
Amneal Pharmaceuticals, Cronos Group, Carriage Services, Business First Bancshares and Amphenol are part of the Zacks Screen of the Week article.
5 Stocks Backed by High Efficiency for Solid Gains Amid Volatility
by Santanu Roy
Invest in stocks of AMRX, CRON, CSV, BFST and APH to tap their high-efficiency levels.
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -8.33% and 75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cronos Group (CRON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Calliditas Therapeutics AB Sponsored ADR (CALT) Surges 16.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Calliditas Therapeutics AB Sponsored ADR (CALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
3 Cannabis Stocks Soaring on HHS' Recommendation to DEA
by Abhinab Dasgupta
Canopy Growth (CGC), Tilray (TLRY) and Cronos (CRON) shoot up on news that the DEA is considering recommendations for low-risk reclassification of marijuana.
Pacira (PCRX) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of -3.70% and 3.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
5 Top-Performing ETFs of Last Week
by Sanghamitra Saha
Wall Street was downbeat due to rising rate worries.
5 Winning Inverse/leveraged ETFs of Last Week
by Sanghamitra Saha
Wall Street was downbeat last week due to rising rate worries.
Cronos Group (CRON) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of 25% and 13.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 4.76% and 1.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Cronos (CRON) Loses -17.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Cronos (CRON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Cronos Group (CRON) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of -180% and 7.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Cronos Group (CRON) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pot Stocks Get Smoked: What's Behind the Move?
by Andrew Rocco
Marijuana-related stocks reversed gains from earlier in the week as revelations emerged that a recent marijuana bill is unlikely to pass.
Cronos Group (CRON) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of -16.67% and 10.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Lags Q3 Earnings Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -9.84% and 2.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cronos Group (CRON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Markets Await July Consumer Price Index Data
by Zacks Equity Research
Markets Await July Consumer Price Index Data
Summer Trading Ahead of CPI Report: Pre-Markets Flat to Down
by Mark Vickery
We see a preliminary non-farm -4.6% in Q2 Productivity, better than the -5% expected and the -7.3% from Q1, which was the worst productivity report since 1947.